2m 2m 2m 2m 2m 2m 2m
ALAUNOS (TCRT)
NASDAQ
$0.86-$0.06 (-6.09%)
Price as of Oct 02, 2026 5:02 PM EDT- $2.3MMarket Cap
- -65.02%1-Year Change
- BiotechnologyIndustry
ALAUNOS (TCRT)
$0.86-$0.06 (-6.09%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 28
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreDay Range
$0.89
$0.95
$0.92
1-Year Range
$0.89
$4.36
$0.92
Latest Close$0.92
Change
+$0.03 (+3.53%)
Volume93,767
Market Cap$2.3M
Shares Outstanding2.5M
P/E (TTM)-0.51
Diluted EPS (TTM)-$1.81
Enterprise Value$2.2M
Information as of 10/01/2026
Company Profile
ALAUNOS THERAPEUTICS INC
https://www.alaunos.com$2.3M
Market Cap
-$4.0M
Net Income
Sector: Healthcare
Industry: Biotechnology
501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
346 355 4099Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Key Executives
- Holger Weis
- Ferdinand Groenewald
Current Ownership Distribution
- Institutions572.1M (76.78%)
- Mutual Funds168.0M (22.55%)
- Insiders5.0M (0.67%)
- Other0 (0.00%)